Significance of Plasma Cytokine Levels in Melanoma Patients With Histologically Negative Sentinel Lymph Nodes

@inproceedings{Porter2001SignificanceOP,
  title={Significance of Plasma Cytokine Levels in Melanoma Patients With Histologically Negative Sentinel Lymph Nodes},
  author={Geoffrey A. Porter and Joseph Abdalla and Meisheng Lu and Shannon Smith and Diane M. Montgomery and Elizabeth Ann Grimm and Merrick I. Ross and Paul F. Mansfield and Jeffrey E Gershenwald and Jeffrey E. Lee},
  year={2001}
}
Introduction:Although sentinel lymph node (SLN) status is the most powerful predictor of prognosis in patients with clinically localized melanoma, a proportion of melanoma patients with histologically negative SLNs will still recur. It is hypothesized that tumor response may be altered or mediated by specific cytokines. We therefore investigated whether levels of IL-4, IL-6, IL-10, TNF-α, or IFN-γ would predict disease recurrence in melanoma patients with histologically negative SLNs. 

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 23 CITATIONS

Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2005
VIEW 3 EXCERPTS
HIGHLY INFLUENCED

Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ

  • The Journal of investigative dermatology
  • 2015
VIEW 1 EXCERPT
CITES BACKGROUND